Rising incidences of cancer is leading to an increase in the scope of work for research and diagnostics companies. Notably, research firm Markets and Markets projects the global cancer diagnostics market to hit $26.6 billion by 2026, witnessing a CAGR of 11.5% between 2021 and 2026. Celcuity (CELC), a leading player in this field, is currently focused on developing its next-generation cancer diagnostic discovery platform — CELsignia. The platform evaluates tumor cells for aberrant signaling in entire key pathways to ascertain the best candidates for targeted therapies.
https://www.tipranks.com/news/article/analysts-say-celcuity-can-change-targeted-therapy-game?utm_source=advfn.com&utm_medium=referral
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Celcuity Charts.
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Celcuity Charts.